BRAIN TUMOUR TREATMENT:
ADVANCED OPTIONS & GLOBAL ACCESS

The 2021 WHO CNS classification formally integrated molecular biomarkers — IDH mutation, 1p/19q co-deletion, TERT, CDKN2A/B — into tumour definitions, replacing the purely histological grading system. This means two tumours that look identical under the microscope are now classified differently based on their molecular profile, with direct implications for treatment.

“Molecular markers are no longer prognostic modifiers — they are type-defining features of every brain tumour diagnosis.”

• Primary Brain Tumours

  Arise from glial cells, neurons, meninges, or lymphocytes within the CNS. Account for ~40% of intracranial tumours. WHO grades 1–4 reflect proliferative potential and molecular risk.

• Brain Metastases (Secondary)

  Far more common than primary tumours — representing ~60% of intracranial malignancies. Most frequently from NSCLC, breast, melanoma, colorectal, and renal cell carcinoma.

• IDH Mutation: The Defining Marker

  IDH1/2 mutation is present in ~70–80% of lower-grade gliomas and defines a distinct biological entity with better prognosis and chemosensitivity compared to IDH-wildtype tumours.

• 1p/19q Co-deletion: Oligodendroglioma

  Co-occurrence of IDH mutation and 1p/19q chromosomal co-deletion defines oligodendroglioma — the most chemosensitive primary brain tumour with the best long-term prognosis.

GBM — WHO grade 4, IDH-wildtype — accounts for 45–50% of all primary malignant brain tumours. Median survival with the Stupp protocol remains 14–16 months, rising to 20–24 months in MGMT-methylated patients.

• The Stupp Protocol: Standard Since 2005

  Concomitant temozolomide (75 mg/m²) during 60 Gy radiotherapy followed by 6 adjuvant TMZ cycles remains the global standard of care for newly diagnosed GBM. MGMT methylation predicts benefit from TMZ.

• Tumour Treating Fields (TTFields)

  The NovoTTF-100A/200A device (Optune) delivers low-intensity alternating electric fields via scalp transducer arrays. The EF-14 trial showed OS improvement to 20.9 months (vs 16.0 mo) when added to adjuvant TMZ in MGMT-methylated GBM.

• Recurrent GBM: The Critical Challenge

  Recurrence occurs in virtually all GBM patients, typically within 6–8 months. Bevacizumab achieves radiological responses (28–35%) but no OS benefit in randomised trials. Clinical trial enrolment is the priority at first recurrence.

The following panel must be tested in every adult patient with a newly diagnosed diffuse glioma. Missing any marker may lead to incorrect classification and suboptimal treatment.

Modern brain tumour surgery at expert centres employs a suite of intraoperative technologies to achieve maximal safe resection — the most important modifiable prognostic factor in glioma surgery.

1. 1

   Neuronavigation Planning

   Preoperative MRI/CT data registered to the patient's head position, providing real-time 3D guidance showing tumour margins and proximity to eloquent structures.

2. 2

   5-ALA Fluorescence-Guided Surgery

   5-Aminolevulinic acid (Gliolan) taken orally 3 hours before surgery is metabolised in high-grade glioma cells to fluorescent protoporphyrin IX, allowing surgeons to visualise tumour tissue not visible under white light.

3. 3

   Awake Craniotomy for Eloquent Tumours

   For tumours in or adjacent to language and motor cortex, patients are kept conscious during resection and asked to perform real-time tasks, allowing the surgeon to identify and preserve functional cortex.

4. 4

   Intraoperative MRI (iMRI)

   MRI performed during surgery while the patient remains under anaesthesia allows real-time assessment of residual tumour and re-entry for further resection before closing.

5. 5

   MEP / SSEP Electrophysiological Monitoring

   Motor evoked potentials and somatosensory evoked potentials provide continuous real-time monitoring of motor and sensory pathways under general anaesthesia.

Stereotactic radiosurgery (SRS) — delivering a precisely focused, ablative radiation dose to a defined intracranial target — is central to treatment of brain metastases and selected primary tumours. Three platforms are in widespread use.

• Gamma Knife (Leksell, Elekta)

  Uses 192 Co-60 sources in a hemispherical array, achieving sub-millimetre precision. The reference standard for brain SRS with the largest published evidence base. Best suited for lesions <3cm and ≤10 brain metastases.

• CyberKnife (Accuray)

  Robotic arm-mounted compact LINAC delivering SRS from multiple non-coplanar angles with real-time tracking. Frameless system; suited for tumours near the skull base or spine. Can deliver SBRT in 3–5 fractions.

• LINAC-Based SRS (HyperArc, BrainLab)

  Modern LINACs with HD-MLC and radiosurgery software can deliver high-quality intracranial SRS. HyperArc (Varian) enables single-isocenter multi-target SRS for multiple brain metastases in a single session.

Particle therapy offers a dosimetric advantage for brain tumours through the Bragg peak — precise dose delivery with minimal exit radiation. This is particularly valuable in paediatric patients and skull base tumours.

• Proton Beam Therapy

  Optimal for paediatric brain tumours (medulloblastoma, ependymoma, craniopharyngioma) where reducing integral brain dose protects against neurocognitive late effects. Also used for skull base chordomas and chondrosarcomas.

• Carbon Ion Therapy (CIRT)

  Higher relative biological effectiveness (RBE ~3) makes CIRT the treatment of choice for radioresistant skull base tumours. SPHIC (Shanghai) and Heidelberg HIT are the principal centres accessible to international patients.

The systemic therapy landscape is evolving rapidly. Patient eligibility for novel agents depends on molecular subtype — making comprehensive biomarker testing essential before any systemic treatment decision.

Checkpoint inhibitors have failed in unselected GBM in randomised trials. However, specific molecular subtypes and novel approaches (personalised vaccines, CAR-T) show emerging signals that are reshaping the clinical trial landscape.

• Personalised Neoantigen Vaccines

  Patient-specific vaccines designed from tumour mutation-derived neoantigens are in active phase I/II trials. Combinatorial use with pembrolizumab and TTFields is under investigation at leading centres.

• CAR-T for Brain Tumours

  Targets include EGFRvIII, IL13Rα2, GD2, B7-H3, and HER2. Early-phase trials show intracranial administration achieves responses. Locoregional delivery (intratumoral/intraventricular) is the most promising route.

• Checkpoint Inhibitors: Why They Have Failed

  Immunosuppressive TME, low mutational burden, and blood-brain barrier exclusion have produced negative phase III results (CheckMate 143, CheckMate 498/548). Biomarker-selected subgroups remain under investigation.

• ONC201 in H3K27M+ Diffuse Midline Glioma

  ONC201 (dordavipone) has demonstrated significant activity in H3K27M-mutant DMG — a previously treatment-refractory entity — with ORR ~18–20% and durable responses. Accessible via expanded access programmes.

Data from landmark trials and population registries defining the current state of brain tumour outcomes.

• 14.6 moGBM Median OS (Stupp Protocol)Rising to 20.9 months with TTFields added in MGMT-methylated patients.
• >14 yrsOligodendroglioma Median OSIDH-mutant, 1p/19q co-deleted tumours treated with RT + PCV chemotherapy.
• 27.7 moPFS with VorasidenibIn IDH-mutant grade 2 glioma (INDIGO trial), vs 11.1 months on placebo.
• 10,000+Annual Brain Tumour Ops (Tiantan)Tiantan Hospital Beijing — Asia's highest-volume neurosurgical centre.

Cost estimates are approximate ranges for the full treatment package (surgery + radiotherapy + initial systemic therapy). Costs exclude ongoing adjuvant chemotherapy cycles, TTFields device rental, and follow-up MRI.

China and India provide access to specialist neuro-oncology, advanced surgical and radiation technology, and comprehensive molecular profiling at a fraction of Western costs. CancerFax navigates patients to the right centre for their specific tumour and needs.

• China: Tiantan Hospital Beijing

  Asia's largest neurosurgical centre with >10,000 brain tumour operations annually. Full intraoperative technology suite (iMRI, 5-ALA, awake craniotomy), Gamma Knife, and access to investigational agents including vorasidenib and CAR-T trials.

• China: SPHIC (Shanghai Proton Centre)

  The Shanghai Proton and Heavy Ion Center is Asia's premier particle therapy facility, offering both proton and carbon ion therapy for brain tumours and skull base cancers.

• India: NIMHANS Bangalore

  India's leading neuroscience institute with comprehensive neuro-oncology, awake craniotomy capability, and molecular diagnostics. Costs 60–70% lower than Western Europe for equivalent procedures.

• India: Fortis / Apollo / Tata Memorial

  Multi-city private hospital networks with modern neurosurgery, Gamma Knife, LINAC-SRS, and neuro-oncology services. Strong options for international patients seeking quality care at accessible cost.

Frequently Asked Questions